JP6823167B2 - ミオスタチン阻害剤の使用および併用療法 - Google Patents

Info

Publication number

JP6823167B2

JP6823167B2 JP2019517209A JP2019517209A JP6823167B2 JP 6823167 B2 JP6823167 B2 JP 6823167B2 JP 2019517209 A JP2019517209 A JP 2019517209A JP 2019517209 A JP2019517209 A JP 2019517209A JP 6823167 B2 JP6823167 B2 JP 6823167B2

Authority

JP

Japan

Prior art keywords

myostatin

muscle

smn

sma

subject

Prior art date

2016-06-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 108010056852 Myostatin Proteins 0.000 title claims description 403
• 239000003112 inhibitor Substances 0.000 title claims description 202
• 102000004472 Myostatin Human genes 0.000 title claims 28
• 238000002648 combination therapy Methods 0.000 title description 46
• 210000003205 muscle Anatomy 0.000 claims description 288
• 102100021947 Survival motor neuron protein Human genes 0.000 claims description 201
• 208000002320 spinal muscular atrophy Diseases 0.000 claims description 185
• 239000003607 modifier Substances 0.000 claims description 170
• 238000011282 treatment Methods 0.000 claims description 94
• 239000003795 chemical substances by application Substances 0.000 claims description 81
• 230000007659 motor function Effects 0.000 claims description 79
• 238000002560 therapeutic procedure Methods 0.000 claims description 78
• 238000000034 method Methods 0.000 claims description 75
• 230000001965 increasing effect Effects 0.000 claims description 40
• 239000000427 antigen Substances 0.000 claims description 38
• 108091007433 antigens Proteins 0.000 claims description 38
• 102000036639 antigens Human genes 0.000 claims description 38
• 201000000585 muscular atrophy Diseases 0.000 claims description 35
• 230000014509 gene expression Effects 0.000 claims description 33
• 239000008194 pharmaceutical composition Substances 0.000 claims description 31
• 150000003384 small molecules Chemical class 0.000 claims description 29
• 206010028289 Muscle atrophy Diseases 0.000 claims description 27
• 230000020763 muscle atrophy Effects 0.000 claims description 25
• 230000004913 activation Effects 0.000 claims description 22
• 238000001415 gene therapy Methods 0.000 claims description 22
• 210000002569 neuron Anatomy 0.000 claims description 21
• 210000000577 adipose tissue Anatomy 0.000 claims description 20
• 230000014616 translation Effects 0.000 claims description 20
• 238000007918 intramuscular administration Methods 0.000 claims description 17
• 239000003623 enhancer Substances 0.000 claims description 13
• 238000011156 evaluation Methods 0.000 claims description 12
• 101150113275 Smn gene Proteins 0.000 claims description 9
• 230000007423 decrease Effects 0.000 claims description 9
• 238000002347 injection Methods 0.000 claims description 6
• 239000007924 injection Substances 0.000 claims description 6
• 238000012153 long-term therapy Methods 0.000 claims description 6
• 238000009256 replacement therapy Methods 0.000 claims description 5
• 238000010253 intravenous injection Methods 0.000 claims description 4
• 229940124272 protein stabilizer Drugs 0.000 claims description 4
• 238000010254 subcutaneous injection Methods 0.000 claims description 4
• 239000007929 subcutaneous injection Substances 0.000 claims description 4
• 238000013518 transcription Methods 0.000 claims description 4
• 230000035897 transcription Effects 0.000 claims description 4
• 108020005544 Antisense RNA Proteins 0.000 claims description 3
• 239000003184 complementary RNA Substances 0.000 claims description 3
• 230000003698 anagen phase Effects 0.000 claims 1
• 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 376
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 107
• 230000000694 effects Effects 0.000 description 82
• 201000010099 disease Diseases 0.000 description 73
• 230000006870 function Effects 0.000 description 69
• 230000005764 inhibitory process Effects 0.000 description 64
• 210000002161 motor neuron Anatomy 0.000 description 64
• 241000699670 Mus sp. Species 0.000 description 58
• 208000021642 Muscular disease Diseases 0.000 description 56
• 239000003814 drug Substances 0.000 description 56
• 230000001195 anabolic effect Effects 0.000 description 55
• 201000009623 Myopathy Diseases 0.000 description 53
• 230000008901 benefit Effects 0.000 description 45
• 238000012360 testing method Methods 0.000 description 42
• 230000001537 neural effect Effects 0.000 description 39
• 230000011664 signaling Effects 0.000 description 36
• 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 35
• 229940124597 therapeutic agent Drugs 0.000 description 35
• 210000004027 cell Anatomy 0.000 description 34
• 230000004220 muscle function Effects 0.000 description 34
• 108090000623 proteins and genes Proteins 0.000 description 34
• 210000001519 tissue Anatomy 0.000 description 33
• 208000035475 disorder Diseases 0.000 description 32
• 206010003694 Atrophy Diseases 0.000 description 30
• 230000037444 atrophy Effects 0.000 description 30
• 230000006378 damage Effects 0.000 description 29
• 210000002027 skeletal muscle Anatomy 0.000 description 28
• 210000001087 myotubule Anatomy 0.000 description 27
• 239000012634 fragment Substances 0.000 description 26
• 241001465754 Metazoa Species 0.000 description 24
• 230000002232 neuromuscular Effects 0.000 description 24
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 23
• 230000036961 partial effect Effects 0.000 description 23
• 239000003102 growth factor Substances 0.000 description 22
• 210000005036 nerve Anatomy 0.000 description 22
• 238000009097 single-agent therapy Methods 0.000 description 22
• 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 21
• 230000009467 reduction Effects 0.000 description 21
• 230000001225 therapeutic effect Effects 0.000 description 21
• 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 20
• 230000002638 denervation Effects 0.000 description 20
• 239000000835 fiber Substances 0.000 description 20
• 230000004044 response Effects 0.000 description 20
• 208000027418 Wounds and injury Diseases 0.000 description 19
• 208000014674 injury Diseases 0.000 description 19
• 230000035772 mutation Effects 0.000 description 18
• 208000018360 neuromuscular disease Diseases 0.000 description 18
• 230000002829 reductive effect Effects 0.000 description 18
• 210000002966 serum Anatomy 0.000 description 18
• 230000015572 biosynthetic process Effects 0.000 description 17
• 229940079593 drug Drugs 0.000 description 17
• 108020004999 messenger RNA Proteins 0.000 description 17
• 230000037257 muscle growth Effects 0.000 description 17
• 230000001771 impaired effect Effects 0.000 description 16
• 102000004169 proteins and genes Human genes 0.000 description 16
• 230000006872 improvement Effects 0.000 description 15
• 206010006895 Cachexia Diseases 0.000 description 14
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 14
• 239000003550 marker Substances 0.000 description 14
• 208000024891 symptom Diseases 0.000 description 14
• 230000003442 weekly effect Effects 0.000 description 14
• 230000001976 improved effect Effects 0.000 description 13
• 238000001243 protein synthesis Methods 0.000 description 13
• 208000029578 Muscle disease Diseases 0.000 description 12
• 239000000090 biomarker Substances 0.000 description 12
• 230000030214 innervation Effects 0.000 description 12
• 239000000203 mixture Substances 0.000 description 12
• 230000003387 muscular Effects 0.000 description 12
• 230000002265 prevention Effects 0.000 description 12
• 230000001737 promoting effect Effects 0.000 description 12
• 208000011580 syndromic disease Diseases 0.000 description 12
• 239000003981 vehicle Substances 0.000 description 12
• WWFDJIVIDXJAQR-FFWSQMGZSA-N 1-[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(S)(=O)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(O)(=S)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](COP(O)(=S)O[C@@H]%11[C@@H](COP(O)(=S)O[C@@H]%12[C@@H](COP(O)(=S)O[C@@H]%13[C@@H](COP(O)(=S)O[C@@H]%14[C@@H](COP(O)(=S)O[C@@H]%15[C@@H](COP(O)(=S)O[C@@H]%16[C@@H](COP(O)(=S)O[C@@H]%17[C@@H](COP(O)(=S)O[C@@H]%18[C@@H](CO)O[C@H]([C@@H]%18OCCOC)n%18cc(C)c(=O)[nH]c%18=O)O[C@H]([C@@H]%17OCCOC)n%17cc(C)c(N)nc%17=O)O[C@H]([C@@H]%16OCCOC)n%16cnc%17c(N)ncnc%16%17)O[C@H]([C@@H]%15OCCOC)n%15cc(C)c(N)nc%15=O)O[C@H]([C@@H]%14OCCOC)n%14cc(C)c(=O)[nH]c%14=O)O[C@H]([C@@H]%13OCCOC)n%13cc(C)c(=O)[nH]c%13=O)O[C@H]([C@@H]%12OCCOC)n%12cc(C)c(=O)[nH]c%12=O)O[C@H]([C@@H]%11OCCOC)n%11cc(C)c(N)nc%11=O)O[C@H]([C@@H]%10OCCOC)n%10cnc%11c(N)ncnc%10%11)O[C@H]([C@@H]9OCCOC)n9cc(C)c(=O)[nH]c9=O)O[C@H]([C@@H]8OCCOC)n8cnc9c(N)ncnc89)O[C@H]([C@@H]7OCCOC)n7cnc8c(N)ncnc78)O[C@H]([C@@H]6OCCOC)n6cc(C)c(=O)[nH]c6=O)O[C@H]([C@@H]5OCCOC)n5cnc6c5nc(N)[nH]c6=O)O[C@H]([C@@H]4OCCOC)n4cc(C)c(N)nc4=O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(=O)[nH]c3=O)O[C@H]([C@@H]2OCCOC)n2cnc3c2nc(N)[nH]c3=O)O[C@H]1n1cnc2c1nc(N)[nH]c2=O WWFDJIVIDXJAQR-FFWSQMGZSA-N 0.000 description 11
• 229950001015 nusinersen Drugs 0.000 description 11
• 102000005962 receptors Human genes 0.000 description 11
• 108020003175 receptors Proteins 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 10
• 230000036982 action potential Effects 0.000 description 10
• 210000000593 adipose tissue white Anatomy 0.000 description 10
• 239000000074 antisense oligonucleotide Substances 0.000 description 10
• 238000012230 antisense oligonucleotides Methods 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 239000013603 viral vector Substances 0.000 description 10
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
• 101150081851 SMN1 gene Proteins 0.000 description 9
• 239000005557 antagonist Substances 0.000 description 9
• 230000015556 catabolic process Effects 0.000 description 9
• 230000007547 defect Effects 0.000 description 9
• 230000008021 deposition Effects 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000004927 fusion Effects 0.000 description 9
• 239000008103 glucose Substances 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 210000001596 intra-abdominal fat Anatomy 0.000 description 9
• 238000005259 measurement Methods 0.000 description 9
• 201000006938 muscular dystrophy Diseases 0.000 description 9
• 238000001356 surgical procedure Methods 0.000 description 9
• 230000009885 systemic effect Effects 0.000 description 9
• 238000001262 western blot Methods 0.000 description 9
• 206010061818 Disease progression Diseases 0.000 description 8
• 206010020880 Hypertrophy Diseases 0.000 description 8
• 241000282567 Macaca fascicularis Species 0.000 description 8
• 102000035195 Peptidases Human genes 0.000 description 8
• 108091005804 Peptidases Proteins 0.000 description 8
• 239000004365 Protease Substances 0.000 description 8
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
• 210000003486 adipose tissue brown Anatomy 0.000 description 8
• 230000002411 adverse Effects 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 230000005750 disease progression Effects 0.000 description 8
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
• 239000003446 ligand Substances 0.000 description 8
• 235000019419 proteases Nutrition 0.000 description 8
• 230000000638 stimulation Effects 0.000 description 8
• 230000005062 synaptic transmission Effects 0.000 description 8
• 206010001497 Agitation Diseases 0.000 description 7
• 206010028311 Muscle hypertrophy Diseases 0.000 description 7
• 102000005604 Myosin Heavy Chains Human genes 0.000 description 7
• 108010084498 Myosin Heavy Chains Proteins 0.000 description 7
• 108010029485 Protein Isoforms Proteins 0.000 description 7
• 102000001708 Protein Isoforms Human genes 0.000 description 7
• 239000000556 agonist Substances 0.000 description 7
• 230000000692 anti-sense effect Effects 0.000 description 7
• 230000009286 beneficial effect Effects 0.000 description 7
• 210000003169 central nervous system Anatomy 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 230000001419 dependent effect Effects 0.000 description 7
• 230000002068 genetic effect Effects 0.000 description 7
• 230000004190 glucose uptake Effects 0.000 description 7
• 210000001352 masseter muscle Anatomy 0.000 description 7
• 230000004060 metabolic process Effects 0.000 description 7
• 238000010172 mouse model Methods 0.000 description 7
• 230000012042 muscle hypertrophy Effects 0.000 description 7
• 230000007170 pathology Effects 0.000 description 7
• 230000000144 pharmacologic effect Effects 0.000 description 7
• 230000017854 proteolysis Effects 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 230000019491 signal transduction Effects 0.000 description 7
• 208000020431 spinal cord injury Diseases 0.000 description 7
• 230000004083 survival effect Effects 0.000 description 7
• 210000004291 uterus Anatomy 0.000 description 7
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
• 241000282693 Cercopithecidae Species 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 208000028389 Nerve injury Diseases 0.000 description 6
• 108091034117 Oligonucleotide Proteins 0.000 description 6
• 230000035508 accumulation Effects 0.000 description 6
• 238000009825 accumulation Methods 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 210000000988 bone and bone Anatomy 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 230000007812 deficiency Effects 0.000 description 6
• 230000006866 deterioration Effects 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 238000007913 intrathecal administration Methods 0.000 description 6
• 230000007774 longterm Effects 0.000 description 6
• 230000008764 nerve damage Effects 0.000 description 6
• 108020004707 nucleic acids Proteins 0.000 description 6
• 102000039446 nucleic acids Human genes 0.000 description 6
• 150000007523 nucleic acids Chemical group 0.000 description 6
• 230000003285 pharmacodynamic effect Effects 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 239000013598 vector Substances 0.000 description 6
• 230000009184 walking Effects 0.000 description 6
• 206010064571 Gene mutation Diseases 0.000 description 5
• 206010022489 Insulin Resistance Diseases 0.000 description 5
• 102000016267 Leptin Human genes 0.000 description 5
• 108010092277 Leptin Proteins 0.000 description 5
• 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 5
• 101150015954 SMN2 gene Proteins 0.000 description 5
• 102100036202 Serum amyloid P-component Human genes 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 108010031318 Vitronectin Proteins 0.000 description 5
• 102100035140 Vitronectin Human genes 0.000 description 5
• 230000000996 additive effect Effects 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 201000011474 congenital myopathy Diseases 0.000 description 5
• 230000002354 daily effect Effects 0.000 description 5
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
• 229960003957 dexamethasone Drugs 0.000 description 5
• 230000002708 enhancing effect Effects 0.000 description 5
• 238000010448 genetic screening Methods 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 229940088597 hormone Drugs 0.000 description 5
• 239000005556 hormone Substances 0.000 description 5
• 238000003384 imaging method Methods 0.000 description 5
• 201000008319 inclusion body myositis Diseases 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 229940039781 leptin Drugs 0.000 description 5
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 5
• 230000033001 locomotion Effects 0.000 description 5
• 210000003141 lower extremity Anatomy 0.000 description 5
• 238000012423 maintenance Methods 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 230000002503 metabolic effect Effects 0.000 description 5
• 230000004898 mitochondrial function Effects 0.000 description 5
• 238000010606 normalization Methods 0.000 description 5
• 239000000902 placebo Substances 0.000 description 5
• 229940068196 placebo Drugs 0.000 description 5
• 230000002980 postoperative effect Effects 0.000 description 5
• 238000011002 quantification Methods 0.000 description 5
• 230000004043 responsiveness Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 230000001988 toxicity Effects 0.000 description 5
• 231100000419 toxicity Toxicity 0.000 description 5
• 210000001364 upper extremity Anatomy 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
• 102000004506 Blood Proteins Human genes 0.000 description 4
• 108010017384 Blood Proteins Proteins 0.000 description 4
• 102100032752 C-reactive protein Human genes 0.000 description 4
• 102100024154 Cadherin-13 Human genes 0.000 description 4
• 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 4
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 4
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 102100037241 Endoglin Human genes 0.000 description 4
• 108010036395 Endoglin Proteins 0.000 description 4
• 206010017076 Fracture Diseases 0.000 description 4
• 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 4
• 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 4
• 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 4
• 102000004877 Insulin Human genes 0.000 description 4
• 108090001061 Insulin Proteins 0.000 description 4
• 201000002481 Myositis Diseases 0.000 description 4
• 208000010316 Myotonia congenita Diseases 0.000 description 4
• 108010045517 Serum Amyloid P-Component Proteins 0.000 description 4
• 229920000147 Styrene maleic anhydride Polymers 0.000 description 4
• 102100024554 Tetranectin Human genes 0.000 description 4
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 4
• 210000001789 adipocyte Anatomy 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000008335 axon cargo transport Effects 0.000 description 4
• 229960000074 biopharmaceutical Drugs 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 230000001925 catabolic effect Effects 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 150000001875 compounds Chemical class 0.000 description 4
• 210000001723 extracellular space Anatomy 0.000 description 4
• 210000003414 extremity Anatomy 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 230000008595 infiltration Effects 0.000 description 4
• 238000001764 infiltration Methods 0.000 description 4
• 238000011221 initial treatment Methods 0.000 description 4
• 229940125396 insulin Drugs 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 238000002595 magnetic resonance imaging Methods 0.000 description 4
• 230000010120 metabolic dysregulation Effects 0.000 description 4
• 230000004118 muscle contraction Effects 0.000 description 4
• 230000003955 neuronal function Effects 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 208000022074 proximal spinal muscular atrophy Diseases 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 229960003604 testosterone Drugs 0.000 description 4
• 230000028973 vesicle-mediated transport Effects 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 108010059616 Activins Proteins 0.000 description 3
• 102100037320 Apolipoprotein A-IV Human genes 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• 102000019034 Chemokines Human genes 0.000 description 3
• 108010012236 Chemokines Proteins 0.000 description 3
• 102000004381 Complement C2 Human genes 0.000 description 3
• 108090000955 Complement C2 Proteins 0.000 description 3
• 102100025877 Complement component C1q receptor Human genes 0.000 description 3
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
• 206010010356 Congenital anomaly Diseases 0.000 description 3
• 208000034656 Contusions Diseases 0.000 description 3
• 102100035233 Furin Human genes 0.000 description 3
• 108090001126 Furin Proteins 0.000 description 3
• 101000762243 Homo sapiens Cadherin-13 Proteins 0.000 description 3
• 101000933665 Homo sapiens Complement component C1q receptor Proteins 0.000 description 3
• 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 3
• 206010061598 Immunodeficiency Diseases 0.000 description 3
• 208000029462 Immunodeficiency disease Diseases 0.000 description 3
• 208000026350 Inborn Genetic disease Diseases 0.000 description 3
• 102100026818 Inhibin beta E chain Human genes 0.000 description 3
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
• 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 3
• 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 3
• 102100032114 Lumican Human genes 0.000 description 3
• 108010076371 Lumican Proteins 0.000 description 3
• 238000012307 MRI technique Methods 0.000 description 3
• 201000002169 Mitochondrial myopathy Diseases 0.000 description 3
• 102000008934 Muscle Proteins Human genes 0.000 description 3
• 108010074084 Muscle Proteins Proteins 0.000 description 3
• 102100040557 Osteopontin Human genes 0.000 description 3
• 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 3
• -1 SMN-C2 Chemical compound 0.000 description 3
• 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 3
• 102100029219 Thrombospondin-4 Human genes 0.000 description 3
• 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 3
• 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 3
• 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 3
• 210000000579 abdominal fat Anatomy 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 239000000488 activin Substances 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 108010073614 apolipoprotein A-IV Proteins 0.000 description 3
• 210000003050 axon Anatomy 0.000 description 3
• 230000002457 bidirectional effect Effects 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• 230000009519 contusion Effects 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 238000002716 delivery method Methods 0.000 description 3
• 201000001981 dermatomyositis Diseases 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 230000005021 gait Effects 0.000 description 3
• 230000009395 genetic defect Effects 0.000 description 3
• 208000016361 genetic disease Diseases 0.000 description 3
• 230000002414 glycolytic effect Effects 0.000 description 3
• 210000004247 hand Anatomy 0.000 description 3
• 238000003119 immunoblot Methods 0.000 description 3
• 230000007813 immunodeficiency Effects 0.000 description 3
• 238000010166 immunofluorescence Methods 0.000 description 3
• 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 210000004717 laryngeal muscle Anatomy 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 210000005228 liver tissue Anatomy 0.000 description 3
• 230000003137 locomotive effect Effects 0.000 description 3
• 238000007726 management method Methods 0.000 description 3
• 230000002438 mitochondrial effect Effects 0.000 description 3
• 230000037230 mobility Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 206010028417 myasthenia gravis Diseases 0.000 description 3
• 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 3
• 230000000926 neurological effect Effects 0.000 description 3
• 210000000715 neuromuscular junction Anatomy 0.000 description 3
• 230000003957 neurotransmitter release Effects 0.000 description 3
• 238000001543 one-way ANOVA Methods 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 230000000241 respiratory effect Effects 0.000 description 3
• 230000000717 retained effect Effects 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 210000000278 spinal cord Anatomy 0.000 description 3
• 239000000021 stimulant Substances 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 230000002123 temporal effect Effects 0.000 description 3
• 238000011287 therapeutic dose Methods 0.000 description 3
• 230000007704 transition Effects 0.000 description 3
• 238000011269 treatment regimen Methods 0.000 description 3
• 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
• 210000001260 vocal cord Anatomy 0.000 description 3
• 230000004584 weight gain Effects 0.000 description 3
• 235000019786 weight gain Nutrition 0.000 description 3
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• STWTUEAWRAIWJG-UHFFFAOYSA-N 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol Chemical compound C1C(C)(C)NC(C)(C)CC1OC1=CC=C(C=2C(=CC(=CC=2)C2=CNN=C2)O)N=N1 STWTUEAWRAIWJG-UHFFFAOYSA-N 0.000 description 2
• HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 2
• 102100022980 ADAMTS-like protein 4 Human genes 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 102000003966 Alpha-1-microglobulin Human genes 0.000 description 2
• 101800001761 Alpha-1-microglobulin Proteins 0.000 description 2
• 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
• 208000031713 Autosomal recessive spastic paraplegia type 20 Diseases 0.000 description 2
• 208000010392 Bone Fractures Diseases 0.000 description 2
• 206010065687 Bone loss Diseases 0.000 description 2
• 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 2
• 102100036849 C-C motif chemokine 24 Human genes 0.000 description 2
• 108010075254 C-Peptide Proteins 0.000 description 2
• 108091033409 CRISPR Proteins 0.000 description 2
• 102100037988 Cartilage acidic protein 1 Human genes 0.000 description 2
• 206010007733 Catabolic state Diseases 0.000 description 2
• 102100035882 Catalase Human genes 0.000 description 2
• 108010053835 Catalase Proteins 0.000 description 2
• 102100032219 Cathepsin D Human genes 0.000 description 2
• 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 description 2
• 102100029057 Coagulation factor XIII A chain Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010053085 Complement Factor H Proteins 0.000 description 2
• 102100035432 Complement factor H Human genes 0.000 description 2
• 102100024340 Contactin-4 Human genes 0.000 description 2
• 102100032323 Corticosteroid-binding globulin Human genes 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 2
• 102000009839 Endothelial Protein C Receptor Human genes 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000001690 Factor VIII Human genes 0.000 description 2
• 108010054218 Factor VIII Proteins 0.000 description 2
• 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
• 102100031752 Fibrinogen alpha chain Human genes 0.000 description 2
• 101710137044 Fibrinogen alpha chain Proteins 0.000 description 2
• 102000002090 Fibronectin type III Human genes 0.000 description 2
• 108050009401 Fibronectin type III Proteins 0.000 description 2
• 102000016970 Follistatin Human genes 0.000 description 2
• 108010014612 Follistatin Proteins 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• 208000002705 Glucose Intolerance Diseases 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 102100027772 Haptoglobin-related protein Human genes 0.000 description 2
• 101710122541 Haptoglobin-related protein Proteins 0.000 description 2
• 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 2
• 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 2
• 206010020100 Hip fracture Diseases 0.000 description 2
• 101000975058 Homo sapiens ADAMTS-like protein 4 Proteins 0.000 description 2
• 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 2
• 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 2
• 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
• 101000918352 Homo sapiens Coagulation factor XIII A chain Proteins 0.000 description 2
• 101000868967 Homo sapiens Corticosteroid-binding globulin Proteins 0.000 description 2
• 101001054832 Homo sapiens Inhibin beta C chain Proteins 0.000 description 2
• 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
• 101000615933 Homo sapiens Phosphoserine aminotransferase Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 101000626163 Homo sapiens Tenascin-X Proteins 0.000 description 2
• 101000626125 Homo sapiens Tetranectin Proteins 0.000 description 2
• 101000633617 Homo sapiens Thrombospondin-4 Proteins 0.000 description 2
• 101000606589 Homo sapiens Xaa-Pro dipeptidase Proteins 0.000 description 2
• 206010021639 Incontinence Diseases 0.000 description 2
• 102100026812 Inhibin beta C chain Human genes 0.000 description 2
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
• 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 2
• 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 2
• 102000003810 Interleukin-18 Human genes 0.000 description 2
• 108090000171 Interleukin-18 Proteins 0.000 description 2
• 102000004125 Interleukin-1alpha Human genes 0.000 description 2
• 108010082786 Interleukin-1alpha Proteins 0.000 description 2
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
• 102100026236 Interleukin-8 Human genes 0.000 description 2
• 108090001007 Interleukin-8 Proteins 0.000 description 2
• 208000026492 Isaac syndrome Diseases 0.000 description 2
• 208000000209 Isaacs syndrome Diseases 0.000 description 2
• 102100033467 L-selectin Human genes 0.000 description 2
• 108090001090 Lectins Proteins 0.000 description 2
• 102000004856 Lectins Human genes 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 102000004318 Matrilysin Human genes 0.000 description 2
• 108090000855 Matrilysin Proteins 0.000 description 2
• 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 2
• 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
• 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
• 102100027159 Membrane primary amine oxidase Human genes 0.000 description 2
• 102100022465 Methanethiol oxidase Human genes 0.000 description 2
• 108700021757 Minicore Myopathy with External Ophthalmoplegia Proteins 0.000 description 2
• 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
• 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 2
• 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 2
• 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 2
• 102100023346 Multimerin-2 Human genes 0.000 description 2
• 102000003505 Myosin Human genes 0.000 description 2
• 108060008487 Myosin Proteins 0.000 description 2
• 206010068871 Myotonic dystrophy Diseases 0.000 description 2
• 102100031900 Neogenin Human genes 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 102000007072 Nerve Growth Factors Human genes 0.000 description 2
• 206010072359 Neuromyotonia Diseases 0.000 description 2
• 102100026747 Osteomodulin Human genes 0.000 description 2
• 102000004264 Osteopontin Human genes 0.000 description 2
• 108010081689 Osteopontin Proteins 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 102000018886 Pancreatic Polypeptide Human genes 0.000 description 2
• 102100020749 Pantetheinase Human genes 0.000 description 2
• 102000003982 Parathyroid hormone Human genes 0.000 description 2
• 108090000445 Parathyroid hormone Proteins 0.000 description 2
• 229940122344 Peptidase inhibitor Drugs 0.000 description 2
• 102100029324 Peptidase inhibitor 16 Human genes 0.000 description 2
• 101710081388 Peptidase inhibitor 16 Proteins 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 2
• 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 2
• 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
• 102000006437 Proprotein Convertases Human genes 0.000 description 2
• 108010044159 Proprotein Convertases Proteins 0.000 description 2
• 102100023087 Protein S100-A4 Human genes 0.000 description 2
• 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 description 2
• 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 108010085149 S100 Calcium-Binding Protein A4 Proteins 0.000 description 2
• 102100028848 Stromelysin-2 Human genes 0.000 description 2
• 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
• 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 2
• 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 2
• 102100024549 Tenascin-X Human genes 0.000 description 2
• 102100026966 Thrombomodulin Human genes 0.000 description 2
• 108010079274 Thrombomodulin Proteins 0.000 description 2
• 102100036034 Thrombospondin-1 Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102100024944 Tropomyosin alpha-4 chain Human genes 0.000 description 2
• 201000003397 Troyer syndrome Diseases 0.000 description 2
• 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 2
• 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 102100028885 Vitamin K-dependent protein S Human genes 0.000 description 2
• 208000005248 Vocal Cord Paralysis Diseases 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 108010023082 activin A Proteins 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 2
• 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000003712 anti-aging effect Effects 0.000 description 2
• 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
• 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
• 230000008236 biological pathway Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 230000007012 clinical effect Effects 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 238000012790 confirmation Methods 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 230000008602 contraction Effects 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 230000018044 dehydration Effects 0.000 description 2
• 238000006297 dehydration reaction Methods 0.000 description 2
• 230000001934 delay Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 230000008472 epithelial growth Effects 0.000 description 2
• 108091022862 fatty acid binding Proteins 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000007446 glucose tolerance test Methods 0.000 description 2
• 108010092206 glutathione S-transferase alpha Proteins 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 229940099472 immunoglobulin a Drugs 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 229940096397 interleukin-8 Drugs 0.000 description 2
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 210000003127 knee Anatomy 0.000 description 2
• 239000002523 lectin Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 210000003784 masticatory muscle Anatomy 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000004630 mental health Effects 0.000 description 2
• 230000007102 metabolic function Effects 0.000 description 2
• 230000037323 metabolic rate Effects 0.000 description 2
• 238000010603 microCT Methods 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 230000037023 motor activity Effects 0.000 description 2
• 230000029712 muscle cell homeostasis Effects 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• 230000001114 myogenic effect Effects 0.000 description 2
• 230000007372 neural signaling Effects 0.000 description 2
• 230000004770 neurodegeneration Effects 0.000 description 2
• 230000006764 neuronal dysfunction Effects 0.000 description 2
• 230000006576 neuronal survival Effects 0.000 description 2
• 239000003900 neurotrophic factor Substances 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 229950009805 onasemnogene abeparvovec Drugs 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 108010078960 osteoadherin Proteins 0.000 description 2
• 239000000199 parathyroid hormone Substances 0.000 description 2
• 229960001319 parathyroid hormone Drugs 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 230000009038 pharmacological inhibition Effects 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 238000003752 polymerase chain reaction Methods 0.000 description 2
• 238000011533 pre-incubation Methods 0.000 description 2
• 210000000229 preadipocyte Anatomy 0.000 description 2
• 201000009104 prediabetes syndrome Diseases 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 238000010966 qNMR Methods 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 210000002235 sarcomere Anatomy 0.000 description 2
• 208000037974 severe injury Diseases 0.000 description 2
• 230000009528 severe injury Effects 0.000 description 2
• 230000003584 silencer Effects 0.000 description 2
• 238000011947 six minute walk test Methods 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 230000001148 spastic effect Effects 0.000 description 2
• 230000009192 sprinting Effects 0.000 description 2
• 210000003699 striated muscle Anatomy 0.000 description 2
• 230000021966 synaptic vesicle transport Effects 0.000 description 2
• 108010013645 tetranectin Proteins 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 208000032521 type II spinal muscular atrophy Diseases 0.000 description 2
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 238000002604 ultrasonography Methods 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• UQIHHGNTYLFRNX-ALKRTJFJSA-N (2s)-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-2-(2-hydroxypropanoylamino)-5-oxopentanoic acid Chemical compound CC(O)C(=O)N[C@H](C(O)=O)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O UQIHHGNTYLFRNX-ALKRTJFJSA-N 0.000 description 1
• ZACWYYKZMLGOTG-UHFFFAOYSA-N 2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-9-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1CN(CC)CCC1C1=CN2C(=O)C=C(C3=NN4C=C(C)N=C(C)C4=C3)N=C2C(C)=C1 ZACWYYKZMLGOTG-UHFFFAOYSA-N 0.000 description 1
• VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
• 101150101604 ACVR1B gene Proteins 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• 208000004611 Abdominal Obesity Diseases 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 102100036664 Adenosine deaminase Human genes 0.000 description 1
• 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 description 1
• 101710161969 Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 description 1
• 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 description 1
• 102100022460 Alpha-1-acid glycoprotein 2 Human genes 0.000 description 1
• 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
• 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
• 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
• 102100034608 Angiopoietin-2 Human genes 0.000 description 1
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
• 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
• 108010081589 Becaplermin Proteins 0.000 description 1
• 102000000119 Beta-lactoglobulin Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 102100036845 C-C motif chemokine 22 Human genes 0.000 description 1
• 108010029697 CD40 Ligand Proteins 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 238000010354 CRISPR gene editing Methods 0.000 description 1
• 102000055006 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• 102100038518 Calcitonin Human genes 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 101710196749 Cartilage acidic protein 1 Proteins 0.000 description 1
• 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
• 206010065941 Central obesity Diseases 0.000 description 1
• 108010083701 Chemokine CCL22 Proteins 0.000 description 1
• 108010083647 Chemokine CCL24 Proteins 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 102100029058 Coagulation factor XIII B chain Human genes 0.000 description 1
• 102100031519 Collagen alpha-1(VI) chain Human genes 0.000 description 1
• 102100024338 Collagen alpha-3(VI) chain Human genes 0.000 description 1
• 108010028780 Complement C3 Proteins 0.000 description 1
• 102000016918 Complement C3 Human genes 0.000 description 1
• 108010027644 Complement C9 Proteins 0.000 description 1
• 102100031037 Complement component C9 Human genes 0.000 description 1
• 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 1
• 101710107714 Contactin-4 Proteins 0.000 description 1
• 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
• 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
• 101710158332 Diuretic hormone Proteins 0.000 description 1
• 101710204261 Diuretic hormone class 2 Proteins 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 206010015548 Euthanasia Diseases 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 108010061932 Factor VIIIa Proteins 0.000 description 1
• 108010074105 Factor Va Proteins 0.000 description 1
• 108010071289 Factor XIII Proteins 0.000 description 1
• 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 1
• 102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 1
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
• 101150027875 Ftl1 gene Proteins 0.000 description 1
• 206010018276 Gingival bleeding Diseases 0.000 description 1
• 208000024283 Gingival haemorrhages Diseases 0.000 description 1
• 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
• 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
• 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
• 108060003393 Granulin Proteins 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
• 108010066705 H-cadherin Proteins 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 102000014702 Haptoglobin Human genes 0.000 description 1
• 108050005077 Haptoglobin Proteins 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 102100032813 Hepatocyte growth factor-like protein Human genes 0.000 description 1
• 101000678195 Homo sapiens Alpha-1-acid glycoprotein 1 Proteins 0.000 description 1
• 101000678191 Homo sapiens Alpha-1-acid glycoprotein 2 Proteins 0.000 description 1
• 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
• 101000732617 Homo sapiens Angiotensinogen Proteins 0.000 description 1
• 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 1
• 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
• 101000932890 Homo sapiens Calcitonin gene-related peptide 1 Proteins 0.000 description 1
• 101000878940 Homo sapiens Cartilage acidic protein 1 Proteins 0.000 description 1
• 101000918350 Homo sapiens Coagulation factor XIII B chain Proteins 0.000 description 1
• 101000941581 Homo sapiens Collagen alpha-1(VI) chain Proteins 0.000 description 1
• 101000909506 Homo sapiens Collagen alpha-3(VI) chain Proteins 0.000 description 1
• 101000909504 Homo sapiens Contactin-4 Proteins 0.000 description 1
• 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
• 101001027663 Homo sapiens Fatty acid-binding protein, heart Proteins 0.000 description 1
• 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 1
• 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
• 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 description 1
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
• 101001004946 Homo sapiens Lactoylglutathione lyase Proteins 0.000 description 1
• 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 description 1
• 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
• 101000822604 Homo sapiens Methanethiol oxidase Proteins 0.000 description 1
• 101001114675 Homo sapiens Multimerin-2 Proteins 0.000 description 1
• 101000636823 Homo sapiens Neogenin Proteins 0.000 description 1
• 101000854777 Homo sapiens Pantetheinase Proteins 0.000 description 1
• 101001090065 Homo sapiens Peroxiredoxin-2 Proteins 0.000 description 1
• 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 1
• 101000596046 Homo sapiens Plastin-2 Proteins 0.000 description 1
• 101000577619 Homo sapiens Profilin-1 Proteins 0.000 description 1
• 101000869693 Homo sapiens Protein S100-A9 Proteins 0.000 description 1
• 101000964691 Homo sapiens Protein Z-dependent protease inhibitor Proteins 0.000 description 1
• 101100203485 Homo sapiens SMN2 gene Proteins 0.000 description 1
• 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 description 1
• 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 1
• 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
• 101001131204 Homo sapiens Sulfhydryl oxidase 1 Proteins 0.000 description 1
• 101000762938 Homo sapiens TOX high mobility group box family member 4 Proteins 0.000 description 1
• 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
• 101000837639 Homo sapiens Thyroxine-binding globulin Proteins 0.000 description 1
• 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
• 101000830781 Homo sapiens Tropomyosin alpha-4 chain Proteins 0.000 description 1
• 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 description 1
• 102000009490 IgG Receptors Human genes 0.000 description 1
• 108010073807 IgG Receptors Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 208000015580 Increased body weight Diseases 0.000 description 1
• 208000011327 Increased bone mineral density Diseases 0.000 description 1
• 102000014429 Insulin-like growth factor Human genes 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• 102100026019 Interleukin-6 Human genes 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 108010060630 Lactoglobulins Proteins 0.000 description 1
• 102100026004 Lactoylglutathione lyase Human genes 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
• 208000035967 Long Term Adverse Effects Diseases 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 108091027974 Mature messenger RNA Proteins 0.000 description 1
• 101710132836 Membrane primary amine oxidase Proteins 0.000 description 1
• 206010068836 Metabolic myopathy Diseases 0.000 description 1
• 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
• 101710134383 Methanethiol oxidase Proteins 0.000 description 1
• 101710130571 Multimerin-2 Proteins 0.000 description 1
• 101100203487 Mus musculus Smn1 gene Proteins 0.000 description 1
• 101100148113 Mus musculus Snrpn gene Proteins 0.000 description 1
• 206010056720 Muscle mass Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 102100038610 Myeloperoxidase Human genes 0.000 description 1
• 108090000235 Myeloperoxidases Proteins 0.000 description 1
• 102100030856 Myoglobin Human genes 0.000 description 1
• 108010062374 Myoglobin Proteins 0.000 description 1
• 206010028629 Myoglobinuria Diseases 0.000 description 1
• 208000023137 Myotoxicity Diseases 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 102000003683 Neurotrophin-4 Human genes 0.000 description 1
• 108090000099 Neurotrophin-4 Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 208000007542 Paresis Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 102100037499 Parkinson disease protein 7 Human genes 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 102100034763 Peroxiredoxin-2 Human genes 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 102000011195 Profilin Human genes 0.000 description 1
• 108050001408 Profilin Proteins 0.000 description 1
• 102100028857 Profilin-1 Human genes 0.000 description 1
• 101800004937 Protein C Proteins 0.000 description 1
• 102000017975 Protein C Human genes 0.000 description 1
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 1
• 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 1
• 108010066124 Protein S Proteins 0.000 description 1
• 102100032420 Protein S100-A9 Human genes 0.000 description 1
• 102100040790 Protein Z-dependent protease inhibitor Human genes 0.000 description 1
• 208000033550 Proximal spinal muscular atrophy type 4 Diseases 0.000 description 1
• 241000269435 Rana <genus> Species 0.000 description 1
• 208000035977 Rare disease Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 102000013674 S-100 Human genes 0.000 description 1
• 108700021018 S100 Proteins 0.000 description 1
• 101000849522 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S13 Proteins 0.000 description 1
• 101000721481 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Succinyl-diaminopimelate desuccinylase Proteins 0.000 description 1
• 101800001700 Saposin-D Proteins 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 101710132826 Selenium-binding protein 1 Proteins 0.000 description 1
• 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
• 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
• 102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
• 108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
• 101150069235 Snrpn gene Proteins 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 1
• 208000033145 Spinal muscular atrophy with respiratory distress type 1 Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 102100034371 Sulfhydryl oxidase 1 Human genes 0.000 description 1
• 102000043168 TGF-beta family Human genes 0.000 description 1
• 108091085018 TGF-beta family Proteins 0.000 description 1
• 102100026749 TOX high mobility group box family member 4 Human genes 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 108010046722 Thrombospondin 1 Proteins 0.000 description 1
• 102100028709 Thyroxine-binding globulin Human genes 0.000 description 1
• 108090000340 Transaminases Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 101710193115 Tropomyosin alpha-4 chain Proteins 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
• 150000001413 amino acids Chemical group 0.000 description 1
• 239000003263 anabolic agent Substances 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 210000002226 anterior horn cell Anatomy 0.000 description 1
• 229930193936 anticarin Natural products 0.000 description 1
• 206010003549 asthenia Diseases 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 239000005441 aurora Substances 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 210000003403 autonomic nervous system Anatomy 0.000 description 1
• 201000000527 autosomal recessive distal spinal muscular atrophy 1 Diseases 0.000 description 1
• 210000001099 axilla Anatomy 0.000 description 1
• 108010023337 axl receptor tyrosine kinase Proteins 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000008436 biogenesis Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037182 bone density Effects 0.000 description 1
• 230000037118 bone strength Effects 0.000 description 1
• 210000003461 brachial plexus Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000001217 buttock Anatomy 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000004640 cellular pathway Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 231100000045 chemical toxicity Toxicity 0.000 description 1
• 230000009194 climbing Effects 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 229940105784 coagulation factor xiii Drugs 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 230000002920 convulsive effect Effects 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000006837 decompression Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 208000021347 distal spinal muscular atrophy 1 Diseases 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 230000004821 effect on bone Effects 0.000 description 1
• 230000000081 effect on glucose Effects 0.000 description 1
• 230000000667 effect on insulin Effects 0.000 description 1
• 230000001094 effect on targets Effects 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 238000003372 electrophysiological method Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 238000005265 energy consumption Methods 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000002360 explosive Substances 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229940028334 follicle stimulating hormone Drugs 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000002695 general anesthesia Methods 0.000 description 1
• 238000010362 genome editing Methods 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 230000014101 glucose homeostasis Effects 0.000 description 1
• 230000036252 glycation Effects 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 201000004502 glycogen storage disease II Diseases 0.000 description 1
• 230000002394 glycogenic effect Effects 0.000 description 1
• ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
• 230000036449 good health Effects 0.000 description 1
• 230000010005 growth-factor like effect Effects 0.000 description 1
• 230000007407 health benefit Effects 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 230000001744 histochemical effect Effects 0.000 description 1
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
• 102000053564 human SMN2 Human genes 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 238000009413 insulation Methods 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 238000002684 laminectomy Methods 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000006372 lipid accumulation Effects 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000004777 loss-of-function mutation Effects 0.000 description 1
• 210000004705 lumbosacral region Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 238000005399 mechanical ventilation Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 208000037226 minicore myopathy Diseases 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 239000002062 molecular scaffold Substances 0.000 description 1
• 238000009126 molecular therapy Methods 0.000 description 1
• 238000011294 monotherapeutic Methods 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 208000010924 multiminicore myopathy Diseases 0.000 description 1
• 238000001964 muscle biopsy Methods 0.000 description 1
• 230000009756 muscle regeneration Effects 0.000 description 1
• 230000036473 myasthenia Effects 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• 210000003365 myofibril Anatomy 0.000 description 1
• 108010076969 neogenin Proteins 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000007383 nerve stimulation Effects 0.000 description 1
• 238000010984 neurological examination Methods 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 229940097998 neurotrophin 4 Drugs 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QNTASHOAVRSLMD-FCARAQADSA-N olesoxime Chemical compound C1CC2=C\C(=N/O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNTASHOAVRSLMD-FCARAQADSA-N 0.000 description 1
• 229950001051 olesoxime Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000000399 optical microscopy Methods 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229960005244 oxymetholone Drugs 0.000 description 1
• ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
• ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 108010029648 pantetheinase Proteins 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 230000008447 perception Effects 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 108010049224 perlecan Proteins 0.000 description 1
• 238000009520 phase I clinical trial Methods 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 210000003105 phrenic nerve Anatomy 0.000 description 1
• 208000024335 physical disease Diseases 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 108010049148 plastin Proteins 0.000 description 1
• 229930192033 plastin Natural products 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 108010066823 proline dipeptidase Proteins 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 238000003614 protease activity assay Methods 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 239000012474 protein marker Substances 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000005086 pumping Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 230000025488 response to cold Effects 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 230000009183 running Effects 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000025185 skeletal muscle atrophy Effects 0.000 description 1
• 210000003875 slow muscle fiber Anatomy 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010972 statistical evaluation Methods 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000013517 stratification Methods 0.000 description 1
• 210000004003 subcutaneous fat Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 239000011885 synergistic combination Substances 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 108010060815 thrombospondin 4 Proteins 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 231100000167 toxic agent Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 102000014898 transaminase activity proteins Human genes 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 210000003945 type 2b muscle cell Anatomy 0.000 description 1
• 208000005606 type IV spinal muscular atrophy Diseases 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 230000002747 voluntary effect Effects 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 210000000636 white adipocyte Anatomy 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 210000000707 wrist Anatomy 0.000 description 1